skip to main |
skip to sidebar
"Amarin Corporation Says Huntington's Disease Drug Failed in Trials
LONDON, April 24 -- Amarin Corporation plc ('Amarin' or the 'Company') today announces top-line results from its two Phase III clinical trials of Miraxion to treat Huntington's disease (HD). The Company conducted two Phase III double-blind, placebo-controlled studies in which HD patients were randomized to receive either placebo or 2 grams (1 gram twice daily) of Miraxion daily for six months. Study data showed no statistically significant difference in either study between Miraxion and placebo with regard to the primary and secondary endpoints."
